M08.451 Pauciarticular juvenile rheumatoid arthritis, right hip

Name of the Condition

• Pauciarticular Juvenile Rheumatoid Arthritis, Right Hip

Summary

Pauciarticular juvenile rheumatoid arthritis is a subtype of juvenile idiopathic arthritis characterized by inflammation in four or fewer joints during the first six months of disease onset. The "right hip" designation specifies the right hip joint as the site of involvement. This condition primarily affects children and adolescents, with symptoms including joint pain, swelling, and stiffness localized to the right hip. Systemic features may be present but are less prominent than in other subtypes.

Causes

The exact cause is unknown, but it is believed to be an autoimmune disorder where the immune system mistakenly attacks healthy joint tissues. Genetic factors and environmental triggers may contribute to disease development, though specific triggers are not well-defined.

Risk Factors

• Age (most commonly diagnosed in children under 16).
• Female gender (higher prevalence, especially in those with ANA positivity).
• Positive antinuclear antibody (ANA) test, which increases risk of uveitis.
• Family history of autoimmune diseases.

Symptoms

• Joint pain, swelling, and stiffness in the right hip, often worse in the morning.
• Reduced range of motion in the affected hip.
• Possible eye inflammation (uveitis), which may be asymptomatic initially.
• Limping or difficulty bearing weight on the right leg.

Diagnosis

Diagnosis involves a combination of clinical evaluation, medical history, and diagnostic tests. Physical examination assesses hip joint involvement, while blood tests (e.g., inflammatory markers, ANA) and imaging (e.g., X-rays, MRI) may be used to confirm inflammation and rule out other conditions. Documentation of joint involvement within six months of onset is critical for classification.

Treatment Options

Treatment focuses on reducing inflammation, preserving joint function, and managing symptoms. Options may include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), physical therapy, and intra-articular corticosteroid injections. Biologic agents may be considered for refractory cases. Regular monitoring for uveitis is recommended in ANA-positive patients.

Prognosis and Follow-Up

Prognosis varies; many children achieve remission, but some may develop chronic joint damage. Early treatment improves outcomes. Follow-up includes regular clinical assessments, imaging to monitor joint health, and screening for uveitis. Long-term management may involve orthopedic or ophthalmologic care.

Complications

• Chronic joint damage or deformity in the right hip.
• Uveitis (eye inflammation), potentially leading to vision impairment.
• Growth disturbances if the hip is affected during development.
• Functional limitations affecting mobility.

Lifestyle & Prevention

• Maintain a balanced diet to support overall health.
• Engage in low-impact exercise (e.g., swimming) to preserve joint mobility.
• Use assistive devices (e.g., crutches) if needed to reduce hip stress.
• Protect the right hip from injury during physical activities.

When to Seek Professional Help

Seek care if symptoms worsen, new joint involvement occurs, or systemic signs (e.g., fever, rash) develop. Prompt evaluation is needed for sudden vision changes, as uveitis may be asymptomatic initially.

Tips for Medical Coders

Document the specific joint (right hip) and confirm the number of joints involved (four or fewer) within six months of onset. Ensure clinical notes support the pauciarticular subtype and exclude other causes of hip inflammation. Code M08.451 is specific to the right hip; use the appropriate laterality code for unilateral involvement.